Lithium affects the brain and body regardless of whether the person taking it has bipolar disorder. In healthy volunteers, therapeutic doses shift emotional processing toward a positive bias, and in people with unipolar depression, lithium augmentation is one of the best-studied strategies for treatment-resistant cases. The drug also appears in research on aggression, cognitive decline, and even the tiny amounts naturally present in tap water. What changes is the reason someone encounters lithium and the dose involved, not whether the element has biological effects.
What Happens in Healthy Volunteers
A handful of studies have given lithium to people with no psychiatric diagnosis at all, and the results are telling. In one controlled experiment, short-term lithium treatment in healthy participants produced a measurable positive emotional bias: subjects became better at recognizing happy facial expressions and were more likely to encode positive self-referent words into memory. Impulsivity and reward-seeking behavior, by contrast, did not change significantly.1Scientific Reports. Lithium effects on impulsivity and emotional processing That finding matters because it suggests lithium does something subtle to emotional tone even when there is no mood disorder to “fix.” Researchers have proposed that this early positive bias in emotional processing could be one mechanism behind lithium’s effectiveness when it is used to treat mood disorders.
On the neurochemistry side, a study measuring brain metabolites in healthy people after two weeks of lithium found that glutamine and combined glutamate-plus-glutamine levels dropped in the basal ganglia, while glutamate alone and GABA did not change significantly.2PubMed. Lithium effects on brain glutamatergic and GABAergic systems of healthy volunteers as measured by proton magnetic resonance spectroscopy In plain terms, lithium was nudging the brain’s excitatory signaling chemistry even in people whose brains were presumably working fine to begin with.
Side Effects in People Without Psychiatric Illness
When researchers kept mentally healthy subjects at standard therapeutic blood levels for six months in a double-blind crossover design, the side effects that emerged were hand tremor and increased thirst with more frequent urination. Neither correlated tightly with the exact blood concentration of lithium, and tremor was most common in people over 60. No initial sedative effect was observed.3PubMed. The profile and severity of lithium-induced side effects in mentally healthy subjects That profile mirrors what bipolar patients report, which reinforces the point that lithium’s physical side effects are driven by the drug’s chemistry, not by the underlying condition being treated.
Over the longer term, the kidney deserves attention. Large epidemiological studies have shown that lithium treatment raises the risk of chronic kidney disease and, in some cases, renal failure. The most frequent kidney-related side effect is increased urine output, a condition called nephrogenic diabetes insipidus, but that alone does not reliably predict declining kidney function.4PubMed Central. Lithium nephrotoxicity For someone without bipolar who might be prescribed lithium for another reason, the kidney risk is exactly the same. Monitoring blood levels and kidney function is standard practice no matter why the prescription was written.
Lithium for Treatment-Resistant Depression
The most common non-bipolar psychiatric use of lithium is as an add-on for people whose depression has not responded to standard antidepressants. This strategy, called lithium augmentation, has been tested in more than 30 open-label studies and 10 placebo-controlled trials. A meta-analysis of those controlled trials found lithium roughly tripled the odds of responding compared to placebo, with a response rate of about 41% versus about 14% in the placebo group.5PubMed. Role of lithium augmentation in the management of major depressive disorder That makes lithium one of the better-supported options for people stuck in a depressive episode that will not lift.
The relapse-prevention data is striking, too. In one double-blind trial of patients with unipolar major depression who had already improved with lithium plus an antidepressant, nearly half the patients switched to placebo relapsed during the continuation phase, including one who died by suicide. None of the patients who stayed on lithium relapsed.6PubMed. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression That was a small trial, but it aligns with the broader pattern: lithium seems to offer something antidepressants alone cannot, even in people who do not cycle into mania.
A recent qualitative review confirmed that lithium remains a cost-effective augmentation strategy for treatment-resistant depression, holding its own against newer options like second-generation antipsychotics and ketamine.7PubMed Central. Lithium Augmentation in Treatment-Resistant Depression: A Qualitative Review of the Literature Despite this, lithium augmentation is underused in clinical practice, partly because clinicians associate it so strongly with bipolar disorder that they forget it has robust evidence elsewhere.
Lithium and Suicide Risk
One of the most discussed properties of lithium is its apparent anti-suicidal effect, and this extends well beyond bipolar disorder. A systematic review and meta-analysis found that in unipolar depression specifically, lithium was associated with a roughly two-thirds reduction in the risk of suicide compared to placebo, and an even more dramatic reduction in total deaths.8PubMed. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis Whether this reflects lithium’s mood-stabilizing properties, its effect on impulsivity, or something else entirely remains an open question.
The picture is not entirely clean, though. A randomized trial of veterans with major depression or bipolar disorder who had recently experienced a suicide-related event found that simply adding lithium to their existing treatment did not reduce the incidence of further suicide-related events.9JAMA Psychiatry. Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder: A Randomized Clinical Trial The takeaway from that trial was not that lithium is useless for suicidality, but that layering it on top of complex existing medication regimens in acutely at-risk patients is not a quick fix. Context matters: the meta-analytic evidence supporting lithium’s anti-suicide effect tends to come from longer-term use, not from crisis intervention.
Trace Lithium in Drinking Water
Perhaps the most intriguing line of evidence involves people who are not taking lithium as a medication at all. Lithium occurs naturally in groundwater at concentrations far below any therapeutic dose, and researchers have repeatedly found that regions with higher natural lithium levels in their tap water tend to have lower suicide rates. A meta-analysis of these ecological studies found a consistent inverse association between lithium concentration in public drinking water and suicide mortality.10PubMed. Association between naturally occurring lithium in drinking water and suicide rates: systematic review and meta-analysis of ecological studies
An Austrian study that specifically accounted for regional differences in lithium prescribing confirmed the association: higher natural lithium levels in the water supply were linked to lower suicide rates for the overall population and for males, even after controlling for how many people in the area were prescribed lithium therapeutically.11PubMed Central. Lithium in drinking water and suicide mortality: interplay with lithium prescriptions A more recent ecological study found that the relationship between water lithium and the ratio of attempted to completed suicides followed a U-shaped curve, suggesting that there may be a “sweet spot” at moderate trace concentrations.12Journal of Affective Disorders Reports. Lithium levels in drinking water predicted the ratio of attempted to completed suicides in regions with high incidence of affective disorders
These are ecological studies, meaning they look at populations rather than individuals. You cannot conclude from them that the lithium in your water is personally protecting you from depression. But the consistency of the finding across countries and decades has fueled serious discussion about whether trace lithium supplementation of water supplies could be a public health intervention. That idea remains controversial and untested in any randomized way.
Reducing Aggression and Impulsivity
Long before lithium’s cognitive and anti-suicide effects attracted attention, researchers noticed it could tamp down impulsive aggression in people who were not psychotic and did not have bipolar disorder. A classic study in inmates with histories of impulsive violent behavior found a significant reduction in aggressive infractions among those given lithium compared to placebo. The authors specifically noted that this effect occurred when the aggressive behavior was not tied to psychosis.13PubMed. The effect of lithium on impulsive aggressive behavior in man This anti-aggression property is thought to be separate from lithium’s mood-stabilizing action, and it has been explored in contexts ranging from brain injury to developmental disabilities.
Cognitive Protection and Neurodegenerative Disease
Some of the most active current research on lithium in non-bipolar populations involves cognitive decline. In a randomized trial of older adults with amnestic mild cognitive impairment, lithium-treated patients remained cognitively and functionally stable over two years while those on placebo declined. After three years, the lithium group also showed changes in cerebrospinal fluid markers associated with Alzheimer’s disease, specifically an increase in amyloid-beta peptide levels, which is considered a favorable sign.14PubMed. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial
Even more remarkably, a study using microdoses of lithium (far below the levels used for bipolar treatment) in Alzheimer’s patients found that the treated group held steady on a standard cognitive test while the control group continued to decline, with the gap becoming significant as early as three months and widening over time.15PubMed. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease A pilot randomized trial published in 2026 in older adults with mild cognitive impairment confirmed that low-dose lithium was safe and well-tolerated in this population, though the study was designed to establish feasibility and generate preliminary effect-size estimates rather than prove efficacy on its own.16JAMA Neurology. Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial
The neuroprotective angle is appealing because it would mean lithium has value for an enormous population of older adults who are at risk for dementia but have no mood disorder. None of these trials are large enough to change clinical practice yet, but they keep pointing in the same direction.
How Lithium Works at a Cellular Level
One reason lithium has such wide-ranging effects is that it acts on signaling pathways that are fundamental to all cells, not just neurons involved in mood regulation. The best-documented target is an enzyme called GSK-3β. Lithium inhibits this enzyme, causing an increase in the phosphorylation that keeps it switched off. This has been demonstrated both in cultured neurons and in live animal brains at concentrations consistent with therapeutic blood levels in humans.17Frontiers in Molecular Neuroscience. Inhibition of GSK3 by lithium, from single molecules to signaling networks 18Frontiers in Cellular Neuroscience. Lithium Inhibits GSK3β and Augments GluN2A Receptor Expression in the Prefrontal Cortex GSK-3β is involved in cell survival, inflammation, and the production of the tau protein tangles associated with Alzheimer’s disease, which helps explain why lithium shows up in research on neurodegeneration as well as mood.
A second proposed mechanism involves the signaling molecule inositol. Lithium reduces brain inositol levels by blocking the enzyme that recycles it.19Biological Psychiatry. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression This was long thought to be the key explanation for lithium’s behavioral effects, but the picture has gotten murkier. Studies in mice engineered to have severely depleted inositol found that the downstream lipid signaling you would expect to be disrupted stayed intact, and the behavioral changes associated with lithium did not appear in animals whose inositol was low for genetic reasons rather than because of lithium exposure.20The FASEB Journal. The inositol depletion hypothesis is not sufficient to explain the behavioral effect of lithium in murine brain 21PubMed. Phosphoinositide deficiency due to inositol depletion is not a mechanism of lithium action in brain In other words, inositol depletion happens when you take lithium, but it does not seem to be the reason lithium changes behavior. Researchers still consider inositol relevant, just not through the pathway originally hypothesized.
The fact that no single mechanism fully accounts for lithium’s effects is both frustrating and informative. It suggests the drug is not a precision tool aimed at one molecular target. It is more like a metabolic nudge that shifts several interlocking systems at once, which is probably why its effects show up in such diverse contexts.
Effects on the Body Clock
Lithium consistently lengthens the internal circadian period in every organism tested, from single cells to rodents to humans. In mice kept in constant darkness, lithium extends the interval between bouts of activity. It also delays and lengthens the cycles of melatonin, body temperature, and clock-gene expression in tissues ranging from the brain’s master clock to peripheral organs like the kidneys.22PubMed Central. The impact of lithium on circadian rhythms and implications for bipolar disorder pharmacotherapy Separate experiments using bioluminescent reporters confirmed that lithium lengthens the period and increases the amplitude of molecular clock oscillations in both the brain and the lungs.23PLOS ONE. Lithium Impacts on the Amplitude and Period of the Molecular Circadian Clockwork
For someone without bipolar disorder, this means lithium could subtly shift their sleep-wake timing. The clinical significance is uncertain for healthy people, but disrupted circadian rhythms are implicated in depression, metabolic syndrome, and neurodegenerative disease. Some researchers speculate that lithium’s circadian effects could partially explain its benefits across such a wide range of conditions, though this remains speculative.
Cellular Aging and Senescence
A newer area of investigation is whether lithium slows cellular aging. In a laboratory study, low-dose lithium reduced markers of senescence in human brain support cells called astrocytes derived from stem cells. Specifically, lithium dampened the inflammatory signaling profile that aging cells produce, a profile that contributes to tissue deterioration over time.24PubMed Central. Microdose lithium reduces cellular senescence in human astrocytes – a potential pharmacotherapy for COVID-19? This is cell-culture work and a long way from proving that lithium extends lifespan in humans, but it does suggest a mechanism that could contribute to the neuroprotective effects observed in the cognitive-decline trials described above.
Pregnancy and Fetal Exposure
When lithium crosses the placenta, the fetus is a person “without bipolar” who is nonetheless exposed to the drug. The main concern is cardiac malformations, particularly a rare heart defect called Ebstein’s anomaly. A large cohort study found that cardiac malformations occurred in about 2.4% of lithium-exposed infants, compared to about 1.2% of unexposed infants. The adjusted risk roughly doubled at moderate doses and roughly tripled at doses above 900 milligrams per day.25PubMed Central. Lithium Use in Pregnancy and the Risk of Cardiac Malformations A prospective study of first-trimester exposures found a similar pattern: cardiovascular anomalies were more frequent in the lithium group, though some resolved on their own, and non-cardiovascular malformations were not significantly different between groups.26PubMed. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study
The absolute risk is still relatively low, and these findings are usually weighed against the risk of untreated severe mood disorder during pregnancy. But for the question of what lithium does to someone without bipolar, fetal exposure is a concrete example of lithium affecting a developing body that has no psychiatric condition. The dose-response relationship in the cardiac malformation data reinforces the broader principle that lithium’s biological effects scale with how much of it is present, whether or not the person (or fetus) has the disorder it is most commonly prescribed for.
From Gout Remedy to Broad-Spectrum Tool
Lithium’s medical history underscores how far its uses extend beyond any single diagnosis. It was first introduced as a treatment for gout in the nineteenth century, on the logic that lithium urate is the most soluble salt of uric acid and would therefore help the body excrete excess urate.27Advances in Inorganic Chemistry. Lithium and Medicine: Inorganic Pharmacology That application turned out to be ineffective at the doses used, but the observation that lithium-treated patients seemed calmer eventually led to its psychiatric use in the mid-twentieth century. The gout chapter is a reminder that lithium was never designed for bipolar disorder. It is a simple ion with broad biological activity, and its association with bipolar is a historical accident as much as a pharmacological destiny. Its effects on enzymes, signaling pathways, circadian clocks, and gene expression happen in every cell that encounters it, regardless of whether that cell belongs to someone carrying a bipolar diagnosis.